Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal...
Pharmaceutical
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
FDA recommends additional revised primary symptom-based endpoints Revive to provide amended statistical analysis plan to support unblinding of the data...
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey
Presence in pharmaceutical industry hotbed allows Elevar to recruit top talent as it continues toward a commercial launch of cancer...
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender OfferCAMBRIDGE, United Kingdom and...
Adaptive Research and AHMC Seton Medical Center Announce Collaboration to Expand Clinical Trial Access to Both In- and Out-Patient Settings
SAN FRANCISCO and DALY CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization...
Journey Medical Corporation to Participate in the 35th Annual ROTH Conference
SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that...
Cerevance Announces Upcoming Presentation at the Alzheimer’s Research UK Conference 2023
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer...
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical...
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD
Figure 1 Fluoresceine angiogram data from three animals treated with NM3086 (bottom) and three that received placebo control. The picture...
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to...
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless...
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular...
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement...
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Into the Dark Into the Dark Campaign ImageEmphasizes challenges faced by patients and clinicians within the first 30 days after...
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)...
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products...